Prelude Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Prelude Therapeutics sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials 1 currently recruiting 8 completed early-phase tilt top decile by trial count

Prelude Therapeutics: 12 sponsored US clinical trials, 1 recruiting.

Prelude Therapeutics sponsors 12 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 8 completed. 0 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Recurrent Glioma, with 1 trials.

Top-decile sponsor footprint

Prelude Therapeutics ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 21/100

8 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

12 total, page 1 of 1

RECRUITING Phase 1

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

NCT07469891
TERMINATED Phase 2

A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

NCT06682806
TERMINATED Phase 1

A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

NCT06560645
COMPLETED Phase 1

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

NCT05665530
COMPLETED Phase 1

PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation

NCT05639751
COMPLETED Phase 1

A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

NCT05538572
TERMINATED Phase 1

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

NCT05107856
COMPLETED Phase 1

A Study of PRT2527 in Participants With Advanced Solid Tumors

NCT05159518
COMPLETED Phase 1

A Study of PRT1419 in Patients With Advanced Solid Tumors

NCT04837677
COMPLETED Phase 1

A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies

NCT04543305
COMPLETED Phase 1

A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas

NCT04089449
COMPLETED Phase 1

A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

NCT03886831

Phase Distribution

PhaseTrial count
Phase 1 11
Phase 2 1

Therapeutic Areas

Recurrent Glioma 1
Advanced Solid Tumor 1

What is open in the Prelude Therapeutics pipeline

1 recruiting of 12 indexed (8% open); 8 completed (67%).

Phase mix: 0 late (III/IV) vs 12 early (I/II) (early-phase heavy).

Top condition: Recurrent Glioma (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Prelude Therapeutics: open-pipeline peers nationwide

Peers matched on 12 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

Prelude Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 10152025 0%5%10%15%20% Total trials Recruiting share Prelude TherapeuticsAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.AngiodynamicsAcrotech BiopharmaAtlanta VA Medical CenterBeacon TherapeuticsBoston VA Research Institute
Prelude Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Prelude Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Prelude Therapeutics page

12 registered trials is a research-attention snapshot, not an endorsement of Prelude Therapeutics or any single study.

  • 1 of Prelude Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Recurrent Glioma is the condition Prelude Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Recurrent Glioma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Prelude Therapeutics pipeline card: 12 registered trials from official public datasets.Report a data error.